Interested in becoming an ACAAI member? Learn more about the benefits of membership and find your place in the College.



Podium to Practice - Advancing Allergy / Immunology Discovery
October 24 - 28, 2024
Boston, MA

Submission Deadline: Monday, August 1, 2024 (5:00 pm CDT).

The College invites you to submit an abstract for the 2024 Annual Scientific Meeting, October 24 - 28, Boston, MA.

Medically Challenging Case Abstract Submission

  • One Presenting Author for each accepted abstract must register for and attend the ACAAI 2024 Annual Scientific Meeting in Boston, MA. Oral and ePoster Presentations are scheduled for in-person presentation. 
  • A Presenting Author must be identified by the submission deadline date for the abstract to be considered for acceptance.
  • Abstracts may be submitted by fellows, members and non-members of the College.
  • ACAAI only accepts original abstracts. Abstracts previously accepted and/or published by other organizations should not be submitted. If an abstract submitted to ACAAI Annual Meeting is accepted for programming and/or publication by another organization prior to its acceptance by ACAAI, it must be withdrawn from consideration for the ACAAI Annual Meeting.
  • ACAAI recognizes the use of generative artificial intelligence (AI) as a powerful tool for educators and researchers and encourages its responsible and ethical use. If any form of generative AI is utilized for this abstract submission, it must be clearly acknowledged in the appropriate section(s) within the abstract content. It is expected that authors will review any AI-generated copy, figures, images, citations, or statements for accuracy and edit accordingly. Presenting inaccurate AI-generated information or failing to acknowledge AI-generated information will result in disqualification.
  • Accepted abstracts will be published in the October online supplement of the Annals of Allergy, Asthma & Immunology.
  • The highest scoring Medically Challenging Case abstracts will be considered for in-person, electronic poster presentation on Friday, Saturday or Sunday.
  • There is a $60 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted.
  • Abstracts must be submitted electronically via the online form, and they must be complete, including the author listing. ACAAI will not accept any abstracts or changes to submitted abstracts after the August 1, 2024 submission deadline.

All accepted Abstracts will be published online as they appear within the ACAAI System as of the deadline date. No changes can be made to the abstract after the close of the submission period.


  • To increase the chance of your abstract being accepted, please have your Program Director or other expert review your abstract prior to submitting.

Medically Challenging Case (MCC) Submissions
MCC Abstracts are an opportunity to present interesting and challenging cases you have management in your hospital or practice. Abstracts in the MCC category can describe the medical management in single or small series of patient cases that highlight:

  1. Uncommon presentations associated with common diagnoses
  2. Novel diagnostic or therapeutic approaches
  3. Unexpected or unusual complications of a disease or its management

Submission Information for Authors.

A limit of 5 authors (total) per abstract may be included.

The College follows the ICMJE quidelines. The ICMJE recommends that authorship be based on the following 4 criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

NOTE: All correspondence regarding the abstract submission will be sent to the abstract submitter at the email address provided at time of submission. It is the responsibility of the submitter to ensure that all information is correct and approved by the participating authors.


As the submitter, you will be the main contact person for the abstract, and as such, it will be your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc.). If you are unwilling or unable to function in this capacity, please designate someone else as the contact person.

It is the responsibility of the submitting author to ensure accuracy of content, spelling and author information, including listing order. Abstracts are directly exported from the submission database for publication.

Please review your submission carefully to make sure that all appropriate data and all authors are listed and in the correct order. Absolutely no abstract changes will be accepted after the submission deadline of August 1, 2024, 5:00 pm (CDT).

Commercial Bias. All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection. 

Abstract Withdrawal. If the Submitter wishes to withdraw his/her abstract from the Annual Meeting program, a written request must be submitted to by August 1, 2024. 

Employees of pharmaceutical or medical device companies or other ACCME-defined *ineligible company(ies) are prohibited from participating as an author or presenter of an oral abstract chosen for presentation during a CME Session; however, they may participate as an author or presenter for an electronic poster session, or an abstract chosen for oral presentation during a non-CME Oral Abstracts session.

*ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies

CME Financial Disclosure
In accordance with the ACCME Standards for Commercial Support the American College of Allergy, Asthma & Immunology (ACAAI), as an accredited provider, must ensure all CME Planners, Speakers, Presenters, Authors involved in the development of CME content and/or presentation of content, disclose to the accredited provider ALL*financial relationship(s) with any ACCME-defined **ineligible company(ies) [see definition of ineligible company below].

**ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies

All authors must complete the online Disclosure of Financial Relationships by August 1, 2024 or their names will be pulled as an abstract author.

Disclosure of relevant financial relationships includes the name of the ineligible company and the relationship. 


  1. You must list your authors in the order in which they should appear in the abstract. Presenting Authors can be included anywhere within the listing and must be designated as the Presenting Author. A limit of 5 authors (total) per abstract may be included. A Presenting Author who will register for the ACAAI 2024 Annual Meeting and appear in-person to present the abstractmust be identified for the abstract to be considered for acceptance.
  2. First Name, Middle Initial and Last Name
  3. Company/Institution Name
  4. City, State and Country (where employed)
  5. Author Email
  6. All authors listed on your abstract will receive an email with a link to complete their disclosure. Please make sure they respond; all authors listed on your abstract are REQUIRED to disclose and it will be your responsibility as the Submitter and/or Presenting Author to follow-up with the other authors to make sure the disclosures have been submitted. They will continue to receive auto-reminders each time an abstract is revised or submitted until they have complied with the disclosure request.
  7. Your abstract WILL NOT be reviewed unless all listed authors have: a) approved the submission of the abstract for consideration for presentation at the ACAAI 2024 Annual Meeting; and b) completed and submitted their online disclosure by August 1, 2024 at 5:00 PM (CDT).


There is a limit of 15 words for the abstract title. Use only standard alpha/numeric characters in your title. Do not use symbols. Capitalize the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of online production. Abbreviations must not be used in the title. The system does not monitor for Title character count. Check to ensure that you have not exceeded the word count limit.

Abstract Length
There is a limit of  250 words for the body of your abstract submission.

Abstract Body
Format the abstract body to include: "Introduction", "Case Description" and "Discussion". Do Not include company names or brand names within the abstract. 

  1. Introduction
  2. Case Description
  3. Discussion

The abstract must contain the words "Introduction", "Case Description" and "Discussion" in the body of your abstract to indicate the start of each new section. The abstract title and author information must not be included in the body of the abstract. Do not include references within the body of your abstract.

Best Results. Best results are achieved by typing directly into the "body" area of the submission form.  If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your results are displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."

Editorial Policies for Authors (ICMJE Guidance)
Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be cited in the reference list. Letters of permission must accompany the manuscript at the time of submission.

Use of Figures. You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.

Medically Challenging Case Abstract Acceptance.

To increase your opportunity of MCC abstract acceptance, submitters are encouraged to include their Program Director as an abstract reviewer in advance of final submission.

If the abstract is accepted for presentation at the ACAAI 2024 Annual Meeting, the submitter will be notified via email in late August/early September. Only the submitter will be notified of abstract presentation programming. Please ensure that all contact information is accurate. The notification will include the scheduled date, time and location of the presentation.

For your convenience, all abstract accepted for poster presentation for the ACAAI 2024 Annual Meeting will be displayed electronically. Complete details regarding the electronic posters will be sent to the submitter of accepted abstracts in late August/early September.

Abstracts accepted for presentation will be grouped by topic, numbered and listed in the program and published in the online October issue of the Annals of Allergy, Asthma and Immunology abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.

Meeting Registration. All Presenting Authors must register for, and attend the ACAAI 2024 Meeting in Boston and pay any applicable registration fees. The meeting registration site will open in late July/early August.


Back to Top